A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).
about
New treatment option for ovarian cancer: PARP inhibitorsTargeted drugs in small-cell lung cancerSmall cell lung cancer (SCLC): no treatment advances in recent yearsCellular and molecular biology of small cell lung cancer: an overviewActivation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung CancerNew Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor ImmunotherapyNew and emerging developments in extensive-stage small cell lung cancer therapeuticsA phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).Consolidative thoracic radiotherapy for extensive stage small cell lung cancerSmall Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?Research progress in the treatment of small cell lung cancer.Hierarchical models for sharing information across populations in phase I dose-escalation studies.The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival.Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.Progress and challenges in the treatment of small cell lung cancer.Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).The development of PARP as a successful target for cancer therapy.[Advances in the Treatment of Relapsed Small Cell Lung Cancer].Advanced small cell lung cancer (SCLC): new challenges and new expectations.
P2860
Q26745614-73A62B6B-867D-407B-B08E-BA861CD020F3Q26767017-6C0E0466-2E4C-418E-B064-79F319D8DDC2Q26767020-C57DA450-642A-46CF-8BDF-849776AD4A67Q26767029-88282278-0635-4D30-9716-C35BAE50BF4EQ27315948-CC893C55-DD5E-49E3-98D3-C50E3D66FF72Q28072045-E07681AA-C074-415D-91E8-A848518457AEQ28076304-B8EFB90A-2292-4F0C-BEAE-062116F711A3Q30275176-CB74E04C-622F-43D0-B564-779BC7DB9745Q33591894-FE378225-2A4C-4D2B-B0A7-472E8181862EQ36811784-7E3CFCAF-A2F4-449B-B40C-4574770074DAQ37604301-351303A1-2FBE-4F07-8326-BA618B9E065AQ38798772-750AA634-3809-4769-A300-72DCF98041D0Q38872456-E7195734-CE62-4E84-9F39-218E195DDC84Q39004424-E137437E-64CD-4465-B9A6-A4396369CAF7Q39272825-84386386-ADC1-4124-B5C0-FF0FC2258170Q42408770-201897D5-5357-42CF-9555-C0FCB7AA15B0Q47278103-F3E0B465-31EF-4089-9048-C2C5ED8E2C42Q53747313-28378BF8-4CFC-45F7-BD84-5F1DCFB87783Q54977232-249AEC77-D887-4A71-8DF1-66B684DD59C0
P2860
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A phase 1 safety study of veli ...... Cancer Research Group (E2511).
@ast
A phase 1 safety study of veli ...... Cancer Research Group (E2511).
@en
type
label
A phase 1 safety study of veli ...... Cancer Research Group (E2511).
@ast
A phase 1 safety study of veli ...... Cancer Research Group (E2511).
@en
prefLabel
A phase 1 safety study of veli ...... Cancer Research Group (E2511).
@ast
A phase 1 safety study of veli ...... Cancer Research Group (E2511).
@en
P2093
P2860
P50
P1433
P1476
A phase 1 safety study of veli ...... Cancer Research Group (E2511).
@en
P2093
Chandra P Belani
Charu Aggarwal
Christine L Hann
Jonathan Dowell
Saad A Khan
Suresh S Ramalingam
Taofeek K Owonikoko
P2860
P356
10.1016/J.LUNGCAN.2015.04.015
P577
2015-05-08T00:00:00Z